Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.
Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.
This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.
The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.
Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.
Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.
High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.
Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss.
Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).
Drug is approved for patients who cannot tolerate or have an inadequate response to other meds.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|